National Cerebral and Cardiovascular Center

Bridgestone Corporation

Osaka University

Kowa Company Limited

Tokyo University of Science Education Foundation Administrative Organization

Tokyo University of Science Educational Foundation Administrative Organization

Mariko Shiba

Tetsuji Yamaoka

Atsushi Yamashita

Satoshi Obika

Tsuyoshi Yamamoto

Takeshi Imanishi

Yasuhide Nakayama

Yoshihito Kato

Atsushi Mahara

Sachiro Kakinoki

Keisuke Narukawa

Hidetaka Torigoe

Yoichi Tachibana

Kiyomi Sasaki

Makoto Nagaishi

Tachibana Yoichi

An object of the present invention is to provide an oligonucleotide useful as a therapeutic agent for dyslipidemia that has excellent binding affinity to the PCSK9 gene as well as stability and safety. The oligonucleotide of the present invention contains a sugar-modified nucleoside, the sugar-modified nucleoside has a bridging structure between 4'-position and 2&#x2032;-position, and the oligonucleotide can bind to the human PCSK9 gene. Also, the present invention provides a therapeutic agent for dyslipidemia containing the oligonucleotide as an active ingredient, and the therapeutic agent preferably contains a bioabsorbable material as a carrier. The bioabsorbable material is preferably atelocollagen or peptide gel.

Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient

To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. The present invention is directed to a compound which is formed of (A) an adsorbent for a pathogen occurring in the blood or lymph, and (B) a ligand which is specific to an organ or cells capable of metabolizing or excreting the pathogen and which is bonded to the adsorbent via a linker or with no linker, and to a drug containing the same.

Drug for suppressing pathogen occurring in vivo

The present invention provides a vector which can make nucleic acids to be an aggregate and locate a vector containing a cationic polymer to surround the aggregate so as to protect the nucleic acids from the enzyme. The vector comprises a polymer having branched chain(s). Preferably, 3, 4, or 6 branched chains are bonded to benzene ring. It is preferable that the number of the branched chains is higher. As the branched chain(s), a vinyl-series acrylic polymer is preferable. The vector is synthesized by reacting a dithiocarbamate compound with an acrylamide monomer for the branched chain(s).

Vector

Growing community of inventors

Suita, Japan

Mariko Shiba